COMP360 approval timing: Compass expects to finish its psilocybin NDA within weeks. See what the FDA voucher target means for a decision.
COMP360 Approval: When Could Compass’s Psilocybin Be Cleared?
read more
Biotech
BioMarin Fabry Deal: What Does It Get for $70 Million Upfront?
BioMarin has licensed HM15421/GC1134A, an early-stage subcutaneous Fabry enzyme therapy, from GC Biopharma and Hanmi Pharm for $70 million upfront.
Extracellular Vesicles in Neurology: Is Translation Outpacing Science?
Extracellular vesicles are attracting growing attention in neurology because they can carry proteins, lipids and nucleic acids between cells and may reflect aspects of the biological state of their cells of origin. Their potential applications include liquid-biopsy...
BBP-418 Approval: When Could BridgeBio’s First LGMD Drug Launch?
BBP-418 approval is due by 27 November 2026. What the FDA is weighing for BridgeBio’s LGMD2I/R9 drug, and what the FORTIFY data show.
The Weakest Link in Your Manuscript May Be the Image You Overlooked
Image duplication, one of the most common image integrity problems in published research, can result from an inadvertent mix-up during figure preparation, reuse that has not been clearly explained, or deliberate fabrication. A 2025 analysis of the Retraction Watch...
Ferring Gameto Acquisition: What Does Ferring Get From the Deal?
The Ferring Gameto acquisition is worth up to $1.3825 billion with milestones. What Ferring gets, Fertilo’s phase 3 status and what to watch.
RNA-LNP Development: Creative Biolabs Links Design, Formulation & Analysis
RNA delivery research is moving beyond conventional lipid nanoparticle (LNP) formulation toward a more systematic understanding of how lipid chemistry, particle organization, and intracellular trafficking influence delivery performance. As researchers confront...
UK Lab Space in 2026: Record Vacancy, Regional Squeeze
UK lab space demand reached a record in 2026. So did UK lab space vacancy. CoStar data shows national laboratory vacancy hit a record 14.3% in the second quarter of 2026. That is more than double the level of two years earlier. Yet some regional science parks say...
Redrawing the Limits of “Undruggable” Proteins
For most of modern target-based drug discovery's history, many biologically important targets have been sidelined as undruggable proteins: structural scaffolds and transcription factors with no active site to inhibit, proteins presenting flat surfaces with no pocket...
When Will Merck KGaA’s Silence Therapeutics Acquisition Close?
Merck KGaA, Darmstadt, Germany, expects the Silence Therapeutics acquisition to close in the first quarter of 2027. It will pay $20.00 in cash per American depositary share (ADS). That values Silence at about $1.3 billion. The companies announced the deal on 19...
Anktiva NHS Access: Can UK Patients Get It for Bladder Cancer?
Anktiva NHS access has no NICE recommendation behind it. The medicine holds a UK licence for BCG-unresponsive bladder cancer. However, NICE ended its appraisal in June 2026 because ImmunityBio did not submit evidence. The question matters again because of a US...
Bispecific T-Cell Engagers in Refractory Autoimmune Disease
Bispecific T-cell engagers, originally developed to redirect immune responses against cancer, are being investigated as potential therapeutic candidates for treatment-refractory autoimmune connective tissue diseases. A 2026 study published in Nature Medicine reported...
Medicine Does Not Run on Blood Alone
Prevention-first urine diagnostics will depend not only on how accurately we can measure disease, but on how often and how easily people can be tested. Blood is medicine's default diagnostic medium for good reasons. It circulates through the whole body, carries a...
ALK7 Obesity Drugs: Who Is Developing Them After Roche’s Rona Deal?
Several companies are now developing ALK7 obesity drugs, but human data remain early. On 13 October 2026, Rona Therapeutics licensed an ALK7-targeting RNAi candidate to Roche. Arrowhead, and SiranBio with GSK, have also disclosed ALK7 programmes. Fierce Biotech...
Beyond Binding: Functional Prediction in GPCR Drug Discovery
In GPCR drug discovery, as elsewhere, teams know the cost of getting early decisions wrong. A corrected JAMA analysis of 63 new drugs and biologics approved by the US Food and Drug Administration between 2009 and 2018 estimated the median capitalised R&D...
Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.
In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...
The Future of Diagnostics Is Molecularly Precise
The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint
ArriVent BioPharma has reported a miss on the primary endpoint of its pivotal Phase 3 trial. The study enrolled patients with EGFR exon 20 insertion lung cancer. The global FURVENT study tested the oral inhibitor firmonertinib against platinum chemotherapy. All...